Form 4: Sutro Biopharma Executive Linda Fitzpatrick Reports Stock Transactions

Linda Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Summary

• On March 1, 2025, Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, engaged in transactions involving common stock and restricted stock units (RSUs).
• Fitzpatrick acquired 6,875 and 13,400 shares of common stock through the vesting of RSUs.
• 8,327 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement at a price of $1.59 per share.
• Following these transactions, Fitzpatrick directly owns 84,900 shares of common stock.
• Additionally, 10,383 shares are indirectly held through the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997.
• Fitzpatrick also holds 13,750 RSUs that vest in 1/4th increments annually beginning March 1, 2024, and 40,200 RSUs that vest in 1/4th increments annually beginning March 1, 2025.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard compensation practices; it doesn't inherently indicate positive or negative sentiment.

Positives

• The vesting of RSUs indicates a continued alignment of the executive's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions have a minor impact on shareholders, reflecting the standard dilution associated with equity compensation plans.

Key Dates